# dievini Hopp Biotech Holding

> dievini Hopp Biotech Holding is a VC fund backing Biotechnology. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Walldorf, Germany
- Total investments: 13
- Last investment: Apr 2022
- Lead investor: 38%
- Last updated: Aug 2026
- Website: https://www.dievini.de

dievini Hopp Biotech Holding is a VC fund in Walldorf focused on Biotechnology and Health Care. Dievini is an active investor in Life and Health Sciences companies and is dedicated to the coaching and support of the management teams in corporate and business development.Dievini’s focus is on innovative therapeutics and diagnostics, which are shown to lead to novel treatment regimens allowing doctors to treat patients with life-threateningdiseases better and safer than they can today. Dievini, therefore, is largely invested in companies with unique and first-in-class diagnosis and therapy approaches.The indication focus is in oncology, neurology, infectious diseases, cell therapy and drug delivery systems. In molecular diagnostics, the primary focus is on systems and products in personalized medicine to support and allow individually improved therapy success with reduced adverse events.Dievini’s activities are geographically centered in Germany and Europe.The companies invested in are actively supported in their global development and business activities by dievini.

## Contacts

5 contacts available for dievini Hopp Biotech Holding. Shizune tracks 3 team members at dievini Hopp Biotech Holding. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dievini-hopp-biotech-holding?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 31% |
| Health Care | 2 | 15% |
| Therapeutics | 2 | 15% |
| Pharmaceutical | 2 | 15% |
| Medical | 1 | 8% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 23% |
| Series D | 2 | 15% |
| Post-IPO Equity | 2 | 15% |
| Series E | 1 | 8% |
| Series F | 1 | 8% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christof Hettich | Co-Founder & MD | 7 | https://shizune.co/investors/profile/christof-hettich |
| Mathias Hothum | Managing Director | 2 | https://shizune.co/investors/profile/mathias-hothum |
| Friedrich Bohlen | Managing Director | 2 | https://shizune.co/investors/profile/friedrich-von-bohlen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Novaliq | Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmetmedical needs of millions of patients with eye diseases. Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development: >> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies. More on www.novaliq.com. | $15M | Venture - Series Unknown | Apr 12, 2022 |  |
| Novaliq | Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmetmedical needs of millions of patients with eye diseases. Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development: >> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies. More on www.novaliq.com. | $15M | Venture - Series Unknown | Apr 12, 2022 |  |
| Heidelberg Pharma Research | Heidelberg Pharma GmbH, a drug development company, provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology inthe fields of oncology or inflammatory/autoimmune diseases. | $15.6M | Post-IPO Equity | Apr 27, 2020 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $104M | Post-IPO Equity | Mar 17, 2020 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $104M | Post-IPO Equity | Mar 17, 2020 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $58M | Series E | Oct 04, 2017 |  |
| CureVac | CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.mRNA programs include novelmRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer. | $108.1M | Series F | Nov 03, 2015 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $24.1M | Series D | Jul 16, 2014 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $13.2M | Series D | Oct 15, 2013 |  |
| CureVac | CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.mRNA programs include novelmRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer. | $87.8M | Series D | Sep 18, 2012 |  |

10 of 13 investments shown.

## Co-investors
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 6 deals together
- [AT Impf](https://shizune.co/investors/profile/at-impf) — VC Fund, 3 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 2 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 2 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 2 deals together
- [SAP](https://shizune.co/investors/profile/sap) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does dievini Hopp Biotech Holding invest in?

dievini Hopp Biotech Holding invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series D stage. Most of the 13 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact dievini Hopp Biotech Holding?

Public channels for dievini Hopp Biotech Holding include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at dievini Hopp Biotech Holding?

The team at dievini Hopp Biotech Holding includes Christof Hettich (Co-Founder & MD), Mathias Hothum (Managing Director) and Friedrich Bohlen (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co